Torrent Pharmaceuticals shares gained 2.03% to trade at ₹4,078.00 in Tuesday's session, making it among the top gainers on the Nifty Next 50 index. According to latest market data, the stock was trading at this level with a slight decline of 0.18% from the previous session's high of ₹4,074.05. The company is included as one of the stocks in the benchmark Nifty Next 50 index, demonstrating its significant market presence and maintaining its position as a key player in the pharmaceutical sector.
The company has demonstrated consistent financial performance with impressive growth metrics. As reported by Moneycontrol, consolidated revenue for the quarter-ending September 2025 stood at ₹3,302 crore, up from ₹2,889 crore in September 2024. The net profit for the same period was ₹591 crore, compared to ₹453 crore in the previous year, while EPS increased from ₹13.37 to ₹17.45. The annual performance shows even stronger growth, with consolidated yearly revenue increasing from ₹10,727.84 crore in 2024 to ₹11,516.09 crore in 2025.
According to the financial data reported by Moneycontrol, the company's EPS improved from ₹48.94 in 2024 to ₹56.47 in 2025, while net profit rose from ₹1,656.38 crore to ₹1,911.25 crore during the same period. The debt-to-equity ratio improved from 0.57 in 2024 to 0.40 in 2025, indicating better financial health. The company's ROE increased from 24.15% in 2024 to 25.17% in 2025, demonstrating enhanced profitability and operational efficiency.
As reported by Moneycontrol, the Board of Directors is scheduled to meet on February 13, 2026, to consider and approve audited financial results for the quarter and nine months ending December 31, 2025. The board will also consider payment of an interim dividend for the year 2025-26. Recent dividend announcements include an interim dividend with an effective date of February 18, 2026, and a final dividend of ₹6 per share (120%) with an effective date of June 20, 2025. An intimation of the acquisition of equity shares of J.B. Chemicals & Pharmaceuticals Limited was announced on February 3, 2026.
According to Moneycontrol analysis, Torrent Pharmaceuticals had a bonus issue with a ratio of 1:1 where the ex-bonus date was July 8, 2022. The company also had a stock split on February 20, 2006, where the old face value was 10 and the new face value was 5. As of February 5, 2026, Moneycontrol analysis indicates a bullish sentiment towards Torrent Pharmaceuticals, supporting the positive market response and investor confidence in the company's prospects. The company's current market position reflects its strong fundamentals and growth trajectory within the competitive pharmaceutical sector.
